Brief: HLS Therapeutics Inc - Reaffirms Peak-Year Sales Forecast For Vascepa
20/07/2020 22:25
July 20 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS INC - REAFFIRMS ITS PEAK-YEAR SALES
FORECAST
FOR VASCEPA
* HLS THERAPEUTICS INC - CADTH RECOMMENDS VASCEPA BE
REIMBURSED
FOR PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE UNDER
CERTAIN CONDITIONS
* HLS THERAPEUTICS INC - PMPRB NOTIFIES HLS THAT VASCEPA'S
INTRODUCTORY PRICE SUBMISSION DID NOT TRIGGER PRICING
INVESTIGATION CRITERIA
Source text for Eikon: ID:nCNWks77ha
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease